Research & Development for heart-related diagnostic and therapeutic products.
Clinical trials in pharmaceutical setup and investigative sites (patients).
FDA requirements for product submission for approval.
Participant, FDA-Sponsored Cardiac Safety Research Consortium.
Dr. Elgebaly’s research resulted in the discovery of the potent tissue-derived
inflammatory mediator, Nourin and its antagonists Cyclosporin H (anti-inflammatory) and
the cardioprotective Cyclocreatine (anti-inflammatory & anti-apoptotic).
Dr. Elgebaly has been awarded millions of dollars to support her research from such
organizations as the NIH, academic institution such the University of Connecticut Faculty
of Medicine as well as the Maryland Technology Development Cooperation, several
pharmaceutical companies, corporate competitive awards and private funding.
Dr. Elgebaly has over 79 publications and one review article, as well as 9 Issued Patents
by the U.S. Patent Office and one pending patent application. She published in peerreviewed
journals, including: Science, J. Thoracic & Cardiovascular Surgery, J. Molecular
and Cellular Cardiology, J. Pathology, J. Transplantation, J Expert Review of
Cardiovascular Therapy, J. Urology, J Pharmacology Experimental Therapy, American
Journal of National Cancer Institute, Current Eye Research, and Journal of
Ophthalmology and Visual Science.
Dr. Elgebaly is also a frequent lecturer in international conferences on the subject of
Nourin, Cyclosporin H, and Cyclocreatine Phosphate. Specifically, Dr. Elgebaly was
invited to present her work by:
1. Nobel Prize Winner in Medicine, Professor Sir John Vane, London, UK,
2. Nobel Prize Winner in Medicine, Professor R. Levi Montalcini, Rome, Italy,
3. Professor Sir Magdy Yacoub in London, United Kingdom.